(Q40477055)

English

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo

scientific article

Statements

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo (English)
M Martín
A Lluch
M A Seguí
M Ramos
E Adrover
A Rodríguez-Lescure
R Grosse
L Calvo
C Fernandez-Chacón
M Roset
A Antón
D Isla
P Martínez del Prado
L Iglesias
J Zaluski
A Arcusa
J M López-Vega
M Muñoz
J R Mel
9 June 2006
1205-1212

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit